Health officials and experts will discuss ways to improve global surveillance of the flu and expedite the selection process for which flu strains to include in the vaccine each year.
Australia's CSL, which completed its acquisition of Novartis' flu vaccines business this year, has launched a AU$1 million share buyback.
As part of its responsibility to prepare for public health threats, the U.S. Department of Health and Human Services' BARDA unit is seeking more effective influenza vaccines to incorporate into its pandemic strategy. Now, it's funding two projects it hopes will help the state of affairs.
Older adults don't have as robust an immune response to the flu vaccine as young people do. So Sanofi Pasteur formulated a higher-dose version of its trivalent Fluzone vaccine, which was found in an economic analysis to result in lower medical costs for older adults.
A day after two high-profile organizations announced successful animal results for their own universal flu vaccine, Madison, WI-based FluGen announced a $12 million Series A round to fund the development of its candidate in the race.
The NIAID may have posted 94% efficacy in mice for its investigational "universal" flu vaccine, but The Scripps Research Institute and partner Johnson & Johnson are hot on its heels.
Madison, WI-based FluGen has raised a $12 million Series A from Venture Investors LLC, the Wisconsin Alumni Research Foundation, the State of Wisconsin Investment Board as well as existing investors led by Knox LLC. The money will fund the first human studies of REDEE FLU, a universal flu vaccine candidate.
CSL is now the second largest flu vaccine manufacturer in the world, thanks to its acquisition of Novartis' flu vaccine business. The company reported a AU$1.9 billion ($1.4 billion) full-year profit, a 6% increase over the previous year.
Novavax is making waves in the influenza space, reporting positive Phase II results for its quadrivalent seasonal flu vaccine on Thursday.
A vaccine against a wide range of flu viruses has long eluded scientists, but NIAID researchers have discovered what could be the foundation of a 'universal' flu vaccine.